Clinically, LAG-3 blockade has been exploited by administering a soluble form of the receptor (IMP321) to patients with viral infections (NCT00354263, NCT00354861) or those with different cancers including melanoma, breast cancer, renal cell carcinoma, and pancreatic cancer (NCT01308294, NCT00349934, NCT00351949, NCT00732082), but has not been tested in AML patients to our knowledge. Here, LAG3 is linked to cancer.